Skip to Content
Søk Menu

Neoadjuvant melanoma: ESMO 2025 updates in 2 minutes

Associate Professor Marco Donia, MD, PhD, University of Copenhagen and Clinician-Scientist at Herlev Hospital, reviews the latest long-term data from ESMO 2025, highlighting why neoadjuvant treatment may outperform adjuvant therapy, and exploring emerging biomarkers and strategies.
Marco Donia

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Teresa Macarulla

ESMO 2025: HER2-Targeted Therapy Advances in BTC

/ Teresa Macarulla
ESMO25NBCN Play the Video 4:06

ESMO 2025: Nye data styrker potensialet for CDK4/6-hemmere ved tidlig brystkreft – Intervju med overlege Egil Støre Blix

/ Egil Støre Blix / Jan Andreasen
BrystkreftESMO25NBCN

Sustained efficacy and quality of life with darolutamide + ADT in mHSPC patients of all ages

/ Jan Andreasen
ESMO25Prostatakreft

RNA Expression Profiles May Guide Future Targeted Therapy in Urothelial Cancer

/ Jan Andreasen
BlærekreftESMO25
Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lungekreft Play the Video 05:43

Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study

/ Igle Jan de Jong / Jan Andreasen
ESMO25

LBA20: Sacituzumab Govitecan Significantly Prolongs PFS versus Chemotherapy in Advanced Triple-Negative Breast Cancer

/ Jan Andreasen
BrystkreftESMO25NBCN
John Crown

ESMO 2025: Ribociclib + NSAI Reduced the Risk of Invasive and Distant Recurrence of HR+/HER2−Early Breast Cancer

/ John Crown
BrystkreftESMO25NBCN Play the Video 03:24
Charles Geyer

ESMO 2025: Paradigm Shift in Breast Cancer Treatment

/ Charles E Geyer Jr.
BrystkreftESMO25NBCN Play the Video 05:53
Back to top